Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stewart, W. F.
Right arrow Articles by Metter, E. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stewart, W. F.
Right arrow Articles by Metter, E. J.
NEUROLOGY 1997;48:626-632
© 1997 American Academy of Neurology

Risk of Alzheimer's disease and duration of NSAID use

Walter F. Stewart, PhD, MPH, Claudia Kawas, MD, Maria Corrada, ScM and E. Jeffrey Metter, MD

From the Department of Epidemiology (Dr. Stewart), Johns Hopkins School of Public Health; Department of Neurology (Dr. Kawas and M. Corrada), Johns Hopkins School of Medicine; and Gerontology Research Center/National Institute on Aging (Drs. Kawas and Metter), Baltimore, MD.
Supported in part by a grant from the National Institute on Aging (NIA) (R01AG08325).
Received May 15, 1996. Accepted in final form August 30, 1996.
Address correspondence and reprint requests to Dr. Walter F. Stewart, Department of Epidemiology, School of Hygiene and Public Health, 615 N. Wolfe Street, Baltimore, MD 21205.

Article abstract-In a longitudinal study of 1,686 participants in the Baltimore Longitudinal Study of Aging, we examined whether the risk of Alzheimer's disease (AD) was reduced among reported users of aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs). In addition, we examined use of acetaminophen, a pain-relief medication with little or no anti-inflammatory activity, to assess the specificity of the association between AD risk and self-reported medications. Information on use of medications was collected during each biennial examination between 1980 and 1995. The relative risk (RR) for AD decreased with increasing duration of NSAID use. Among those with 2 or more years of reported NSAID use, the RR was 0.40 (95% confidence interval [CI]: 0.19-0.84) compared with 0.65 (95% CI: 0.33-1.29) for those with less than 2 years of NSAID use. The overall RR for AD among aspirin users was 0.74 (95% CI: 0.46-1.18), and no trend of decreasing risk of AD was observed with increasing duration of aspirin use. No association was found between AD risk and use of acetaminophen (RR = 1.35; 95% CI: 0.79-2.30), and there was no trend of decreasing risk with increasing duration of use. These findings are consistent with evidence from cross-sectional studies indicating protection against AD risk among NSAID users and with evidence suggesting that one stage of the pathophysiology leading to AD is characterized by an inflammatory process.

NEUROLOGY 1997;48: 626-632




This article has been cited by other articles:


Home page
NeurologyHome page
C. A. Szekely, R. C. Green, J.C.S. Breitner, T. Ostbye, A. S. Beiser, M. M. Corrada, H. H. Dodge, M. Ganguli, C. H. Kawas, L. H. Kuller, et al.
No advantage of A{beta}42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies
Neurology, June 10, 2008; 70(24): 2291 - 2298.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
Z. Arvanitakis, F. Grodstein, J. L. Bienias, J. A. Schneider, R. S. Wilson, J. F. Kelly, D. A. Evans, and D. A. Bennett
Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology
Neurology, June 3, 2008; 70(23): 2219 - 2225.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
L. A. Kotilinek, M. A. Westerman, Q. Wang, K. Panizzon, G. P. Lim, A. Simonyi, S. Lesne, A. Falinska, L. H. Younkin, S. G. Younkin, et al.
Cyclooxygenase-2 inhibition improves amyloid-{beta}-mediated suppression of memory and synaptic plasticity
Brain, March 1, 2008; 131(3): 651 - 664.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
C. A. Szekely, J.C.S. Breitner, A. L. Fitzpatrick, T. D. Rea, B. M. Psaty, L. H. Kuller, and P. P. Zandi
NSAID use and dementia risk in the Cardiovascular Health Study*: Role of APOE and NSAID type
Neurology, January 1, 2008; 70(1): 17 - 24.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
K. M. Hayden, P. P. Zandi, A. S. Khachaturian, C. A. Szekely, M. Fotuhi, M. C. Norton, J. T. Tschanz, C. F. Pieper, C. Corcoran, C. G. Lyketsos, et al.
Does NSAID use modify cognitive trajectories in the elderly?: The Cache County Study
Neurology, July 17, 2007; 69(3): 275 - 282.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
R. J Prettyman
Too little, too late?
BMJ, May 26, 2007; 334(7603): 1071 - 1071.
[Full Text] [PDF]


Home page
APPI Online CMEHome page
References
PsychiatryOnline CME, May 1, 2007; 2007(1): 2 - 2.
[Full Text]


Home page
Ann. N. Y. Acad. Sci.Home page
S. POZZI, V. BENEDUSI, A. MAGGI, and E. VEGETO
Estrogen Action in Neuroprotection and Brain Inflammation
Ann. N.Y. Acad. Sci., November 1, 2006; 1089(1): 302 - 323.
[Abstract] [Full Text] [PDF]


Home page
Am J EpidemiolHome page
T.-P. Ng, P.-C. Chiam, T. Lee, H.-C. Chua, L. Lim, and E.-H. Kua
Curry Consumption and Cognitive Function in the Elderly
Am. J. Epidemiol., November 1, 2006; 164(9): 898 - 906.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
K. Tahara, H.-D. Kim, J.-J. Jin, J. A. Maxwell, L. Li, and K.-i. Fukuchi
Role of toll-like receptor signalling in A{beta} uptake and clearance
Brain, November 1, 2006; 129(11): 3006 - 3019.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. A. Culbert, S. D. Skaper, D. R. Howlett, N. A. Evans, L. Facci, P. E. Soden, Z. M. Seymour, F. Guillot, M. Gaestel, and J. C. Richardson
MAPK-activated Protein Kinase 2 Deficiency in Microglia Inhibits Pro-inflammatory Mediator Release and Resultant Neurotoxicity: RELEVANCE TO NEUROINFLAMMATION IN A TRANSGENIC MOUSE MODEL OF ALZHEIMER DISEASE
J. Biol. Chem., August 18, 2006; 281(33): 23658 - 23667.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M.-S. Yang, K.-A. Ji, S.-B. Jeon, B.-K. Jin, S. U. Kim, I. Jou, and E. Joe
Interleukin-13 Enhances Cyclooxygenase-2 Expression in Activated Rat Brain Microglia: Implications for Death of Activated Microglia
J. Immunol., July 15, 2006; 177(2): 1323 - 1329.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
E. Vegeto, S. Belcredito, S. Ghisletti, C. Meda, S. Etteri, and A. Maggi
The Endogenous Estrogen Status Regulates Microglia Reactivity in Animal Models of Neuroinflammation
Endocrinology, May 1, 2006; 147(5): 2263 - 2272.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
I. Mohri, M. Taniike, H. Taniguchi, T. Kanekiyo, K. Aritake, T. Inui, N. Fukumoto, N. Eguchi, A. Kushi, H. Sasai, et al.
Prostaglandin D2-mediated microglia/astrocyte interaction enhances astrogliosis and demyelination in twitcher.
J. Neurosci., April 19, 2006; 26(16): 4383 - 4393.
[Abstract] [Full Text] [PDF]


Home page
J Geriatr Psychiatry NeurolHome page
A. B. Zonderman
Predicting Alzheimer's Disease in the Baltimore Longitudinal Study of Aging
J Geriatr Psychiatry Neurol, December 1, 2005; 18(4): 192 - 195.
[Abstract] [PDF]


Home page
J. Neurosci.Home page
X. Liang, Q. Wang, T. Hand, L. Wu, R. M. Breyer, T. J. Montine, and K. Andreasson
Deletion of the Prostaglandin E2 EP2 Receptor Reduces Oxidative Damage and Amyloid Burden in a Model of Alzheimer's Disease
J. Neurosci., November 2, 2005; 25(44): 10180 - 10187.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
K. P. Townsend and D. Pratico
Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs
FASEB J, October 1, 2005; 19(12): 1592 - 1601.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
M. Kitazawa, S. Oddo, T. R. Yamasaki, K. N. Green, and F. M. LaFerla
Lipopolysaccharide-Induced Inflammation Exacerbates Tau Pathology by a Cyclin-Dependent Kinase 5-Mediated Pathway in a Transgenic Model of Alzheimer's Disease
J. Neurosci., September 28, 2005; 25(39): 8843 - 8853.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
J. Koenigsknecht-Talboo and G. E. Landreth
Microglial Phagocytosis Induced by Fibrillar {beta}-Amyloid and IgGs Are Differentially Regulated by Proinflammatory Cytokines
J. Neurosci., September 7, 2005; 25(36): 8240 - 8249.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
F. SOHRABJI
Estrogen: A Neuroprotective or Proinflammatory Hormone? Emerging Evidence from Reproductive Aging Models
Ann. N.Y. Acad. Sci., June 1, 2005; 1052(1): 75 - 90.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
M. T. Heneka, M. Sastre, L. Dumitrescu-Ozimek, A. Hanke, I. Dewachter, C. Kuiperi, K. O'Banion, T. Klockgether, F. Van Leuven, and G. E. Landreth
Acute treatment with the PPAR{gamma} agonist pioglitazone and ibuprofen reduces glial inflammation and A{beta}1-42 levels in APPV717I transgenic mice
Brain, June 1, 2005; 128(6): 1442 - 1453.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
T. J. Montine and J. D. Morrow
Fatty Acid Oxidation in the Pathogenesis of Alzheimer's Disease
Am. J. Pathol., May 1, 2005; 166(5): 1283 - 1289.
[Abstract] [Full Text] [PDF]


Home page
Am J EpidemiolHome page
A. J. M. de Craen, J. Gussekloo, B. Vrijsen, and R. G. J. Westendorp
Meta-Analysis of Nonsteroidal Antiinflammatory Drug Use and Risk of Dementia
Am. J. Epidemiol., January 15, 2005; 161(2): 114 - 120.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
G. M. COLE, T. MORIHARA, G. P. LIM, F. YANG, A. BEGUM, and S. A. FRAUTSCHY
NSAID and Antioxidant Prevention of Alzheimer's Disease: Lessons from In Vitro and Animal Models
Ann. N.Y. Acad. Sci., December 1, 2004; 1035(1): 68 - 84.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
M. KITAZAWA, T. R. YAMASAKI, and F. M. LAFERLA
Microglia as a Potential Bridge between the Amyloid {beta}-Peptide and Tau
Ann. N.Y. Acad. Sci., December 1, 2004; 1035(1): 85 - 103.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
P. L. McGEER and E. G. McGEER
Inflammation and the Degenerative Diseases of Aging
Ann. N.Y. Acad. Sci., December 1, 2004; 1035(1): 104 - 116.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
N. H. GREIG, M. P. MATTSON, T. PERRY, S. L. CHAN, T. GIORDANO, K. SAMBAMURTI, J. T. ROGERS, H. OVADIA, and D. K. LAHIRI
New Therapeutic Strategies and Drug Candidates for Neurodegenerative Diseases: p53 and TNF-{alpha} Inhibitors, and GLP-1 Receptor Agonists
Ann. N.Y. Acad. Sci., December 1, 2004; 1035(1): 290 - 315.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
I. E. Camacho, L. Serneels, K. Spittaels, P. Merchiers, D. Dominguez, and B. De Strooper
Peroxisome Proliferator-Activated Receptor {gamma} Induces a Clearance Mechanism for the Amyloid-{beta} Peptide
J. Neurosci., December 1, 2004; 24(48): 10908 - 10917.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
S. Sung, H. Yang, K. Uryu, E. B. Lee, L. Zhao, D. Shineman, J. Q. Trojanowski, V. M.-Y. Lee, and D. Pratico
Modulation of Nuclear Factor-{kappa}B Activity by Indomethacin Influences A{beta} Levels but Not A{beta} Precursor Protein Metabolism in a Model of Alzheimer's Disease
Am. J. Pathol., December 1, 2004; 165(6): 2197 - 2206.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S.-Y. Lim, J.-H. Jang, H.-K. Na, S. C. Lu, I. Rahman, and Y.-J. Surh
15-Deoxy-{Delta}12,14-Prostaglandin J2 Protects against Nitrosative PC12 Cell Death through Up-regulation of Intracellular Glutathione Synthesis
J. Biol. Chem., October 29, 2004; 279(44): 46263 - 46270.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
D. L. Simmons, R. M. Botting, and T. Hla
Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition
Pharmacol. Rev., September 1, 2004; 56(3): 387 - 437.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
J Cervilla, M Prince, S Joels, S Lovestone, and A Mann
Premorbid cognitive testing predicts the onset of dementia and Alzheimer's disease better than and independently of APOE genotype
J. Neurol. Neurosurg. Psychiatry, August 1, 2004; 75(8): 1100 - 1106.
[Abstract] [Full Text] [PDF]


Home page
Sci Aging Knowl EnvironHome page
P. L. McGeer and E. McGeer
Immunotherapy for Alzheimer's Disease
Sci. Aging Knowl. Environ., July 7, 2004; 2004(27): pe29 - pe29.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
L. Gan, S. Ye, A. Chu, K. Anton, S. Yi, V. A. Vincent, D. von Schack, D. Chin, J. Murray, S. Lohr, et al.
Identification of Cathepsin B as a Mediator of Neuronal Death Induced by A{beta}-activated Microglial Cells Using a Functional Genomics Approach
J. Biol. Chem., February 13, 2004; 279(7): 5565 - 5572.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
B. McMahon and C. Godson
Lipoxins: endogenous regulators of inflammation
Am J Physiol Renal Physiol, February 1, 2004; 286(2): F189 - F201.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
S.-Y. LIM, J.-H. JANG, and Y.-J. SURH
Induction of Cyclooxygenase-2 and Peroxisome Proliferator-Activated Receptor-{gamma} during Nitric Oxide-Induced Apoptotic PC12 Cell Death
Ann. N.Y. Acad. Sci., December 1, 2003; 1010(1): 648 - 658.
[Abstract] [Full Text] [PDF]


Home page
Evid. Based Ment. HealthHome page
R. Jacoby
Rofecoxib or naproxen do not slow progression of mild to moderate Alzheimer's disease
Evid. Based Ment. Health, November 1, 2003; 6(4): 110 - 110.
[Full Text] [PDF]


Home page
J. Neurosci.Home page
M. Sastre, I. Dewachter, G. E. Landreth, T. M. Willson, T. Klockgether, F. van Leuven, and M. T. Heneka
Nonsteroidal Anti-Inflammatory Drugs and Peroxisome Proliferator-Activated Receptor-{gamma} Agonists Modulate Immunostimulated Processing of Amyloid Precursor Protein through Regulation of {beta}-Secretase
J. Neurosci., October 29, 2003; 23(30): 9796 - 9804.
[Abstract] [Full Text] [PDF]


Home page
Sci Aging Knowl EnvironHome page
L. Helmuth
Detangling Alzheimer's Disease
Sci. Aging Knowl. Environ., October 29, 2003; 2003(43): oa2 - 2.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
R. Flower
What are all the things that aspirin does?
BMJ, September 13, 2003; 327(7415): 572 - 573.
[Full Text] [PDF]


Home page
J Am Board Fam MedHome page
T. C. Rosenthal and N. Khotianov
Managing Alzheimer Dementia Tomorrow
J Am Board Fam Med, September 1, 2003; 16(5): 423 - 434.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
S. Weggen, J. L. Eriksen, S. A. Sagi, C. U. Pietrzik, V. Ozols, A. Fauq, Todd. E. Golde, and E. H. Koo
Evidence That Nonsteroidal Anti-inflammatory Drugs Decrease Amyloid {beta}42 Production by Direct Modulation of {gamma}-Secretase Activity
J. Biol. Chem., August 22, 2003; 278(34): 31831 - 31837.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
Q. Yan, J. Zhang, H. Liu, S. Babu-Khan, R. Vassar, A. L. Biere, M. Citron, and G. Landreth
Anti-Inflammatory Drug Therapy Alters {beta}-Amyloid Processing and Deposition in an Animal Model of Alzheimer's Disease
J. Neurosci., August 20, 2003; 23(20): 7504 - 7509.
[Abstract] [Full Text] [PDF]


Home page
Arch NeurolHome page
H. Chen, S. M. Zhang, M. A. Hernan, M. A. Schwarzschild, W. C. Willett, G. A. Colditz, F. E. Speizer, and A. Ascherio
Nonsteroidal Anti-inflammatory Drugs and the Risk of Parkinson Disease
Arch Neurol, August 1, 2003; 60(8): 1059 - 1064.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
M. Etminan, S. Gill, and A. Samii
Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies
BMJ, July 17, 2003; 327(7407): 128.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
H. C. Salzberg-Brenhouse, E.-Y. Chen, D. F. Emerich, S. Baldwin, K. Hogeland, S. Ranelli, D. Lafreniere, B. Perdomo, L. Novak, T. Kladis, et al.
Inhibitors of Cyclooxygenase-2, but Not Cyclooxygenase-1 Provide Structural and Functional Protection against Quinolinic Acid-Induced Neurodegeneration
J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 218 - 228.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
P. S. Aisen, K. A. Schafer, M. Grundman, E. Pfeiffer, M. Sano, K. L. Davis, M. R. Farlow, S. Jin, R. G. Thomas, and L. J. Thal
Effects of Rofecoxib or Naproxen vs Placebo on Alzheimer Disease Progression: A Randomized Controlled Trial
JAMA, June 4, 2003; 289(21): 2819 - 2826.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
N. M. Gajraj
Cyclooxygenase-2 Inhibitors
Anesth. Analg., June 1, 2003; 96(6): 1720 - 1738.
[Full Text] [PDF]


Home page
AJGPHome page
F. Landi, M. Cesari, G. Onder, A. Russo, S. Torre, and R. Bernabei
Non-Steroidal Anti-Inflammatory Drug (NSAID) Use and Alzheimer Disease in Community-Dwelling Elderly Patients
Am J Geriatr Psychiatry, April 1, 2003; 11(2): 179 - 185.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
M. E. Bamberger, M. E. Harris, D. R. McDonald, J. Husemann, and G. E. Landreth
A Cell Surface Receptor Complex for Fibrillar beta -Amyloid Mediates Microglial Activation
J. Neurosci., April 1, 2003; 23(7): 2665 - 2674.
[Abstract] [Full Text] [PDF]


Home page
Arch NeurolHome page
S. H. Graham and R. W. Hickey
Cyclooxygenases in Central Nervous System Diseases: A Special Role for Cyclooxygenase 2 in Neuronal Cell Death
Arch Neurol, April 1, 2003; 60(4): 628 - 630.
[Full Text] [PDF]


Home page
Epidemiol RevHome page
B. A. in 't Veld, L. J. Launer, M. M. B. Breteler, A. Hofman, and B. H. Ch. Stricker
Pharmacologic Agents Associated with a Preventive Effect on Alzheimer's Disease: A Review of the Epidemiologic Evidence
Epidemiol. Rev., December 1, 2002; 24(2): 248 - 268.
[Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
K. P. TOWNSEND, D. OBREGON, A. QUADROS, N. PATEL, Ch. VOLMAR, D. PARIS, and M. MULLAN
Proinflammatory and Vasoactive Effects of A{beta} in the Cerebrovasculature
Ann. N.Y. Acad. Sci., November 1, 2002; 977(1): 65 - 76.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
Y. Cui, Y. Le, H. Yazawa, W. Gong, and J. M. Wang
Potential role of the formyl peptide receptor-like 1 (FPRL1) in inflammatory aspects of Alzheimer's disease
J. Leukoc. Biol., October 1, 2002; 72(4): 628 - 635.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
P. P. Zandi, J. C. Anthony, K. M. Hayden, K. Mehta, L. Mayer, and J. C.S. Breitner
Reduced incidence of AD with NSAID but not H2 receptor antagonists: The Cache County Study
Neurology, September 24, 2002; 59(6): 880 - 886.
[Abstract] [Full Text] [PDF]


Home page
Am J EpidemiolHome page
J. Lindsay, D. Laurin, R. Verreault, R. Hebert, B. Helliwell, G. B. Hill, and I. McDowell
Risk Factors for Alzheimer's Disease: A Prospective Analysis from the Canadian Study of Health and Aging
Am. J. Epidemiol., September 1, 2002; 156(5): 445 - 453.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
Y.-H. Suh and F. Checler
Amyloid Precursor Protein, Presenilins, and alpha -Synuclein: Molecular Pathogenesis and Pharmacological Applications in Alzheimer's Disease
Pharmacol. Rev., September 1, 2002; 54(3): 469 - 525.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Avramovich, T. Amit, and M. B. H. Youdim
Non-steroidal Anti-inflammatory Drugs Stimulate Secretion of Non-amyloidogenic Precursor Protein
J. Biol. Chem., August 23, 2002; 277(35): 31466 - 31473.
[Abstract] [Full Text] [PDF]


Home page
Sci Aging Knowl EnvironHome page
P. L. McGeer and E. G. McGeer
Innate Immunity, Local Inflammation, and Degenerative Disease
Sci. Aging Knowl. Environ., July 24, 2002; 2002(29): re3 - 3.
[Abstract] [Full Text] [PDF]


Home page